Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...
Contract Pharma15d
Neurocrine Biosciences Appoints SVP of Drug Development, Delivery and Device
“Andy brings unparalleled leadership and experience to Neurocrine’s R&D team,” Neurocrine Biosciences Chief Scientific Officer Jude Onyia, Ph.D., said. “He joins at a critical and exciting time for ...
ETF Daily News15d
Research Analysts Issue Forecasts for NBIX FY2025 Earnings
Also, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of ...
The Pharma Letter15d
Neurocrine appoints Andrew Ratz as senior VP
Chief scientific officer Jude Onyia said: “Andy brings unparalleled leadership and experience to Neurocrine's R&D team,” adding: “He joins at a critical and exciting time as we strive to discover and ...
abc2715d
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development ...
Yahoo Finance16d
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
"Andy brings unparalleled leadership and experience to Neurocrine's R&D team," Neurocrine Biosciences Chief Scientific Officer Jude Onyia, Ph.D., said. "He joins at a critical and exciting time for ...